Melbourne Gene-Editing Therapy Halves Bad Cholesterol in Humans
Melbourne Gene-Editing Therapy Halves Bad Cholesterol in Humans
Australian researchers report a first-in-human gene-editing therapy that cuts LDL cholesterol and triglycerides by about half in patients with hard-to-treat lipid disorders.
Researchers in Melbourne have unveiled the first-in-human trial of a breakthrough gene-editing therapy aimed at difficult-to-treat lipid disorders. In early results, participants saw roughly a 50% drop in LDL cholesterol and triglycerides, offering a potential new option for patients who don’t respond well to statins or other therapies.
The approach uses a precise genetic edit to dial down lipid production, targeting pathways that raise levels of 'bad' cholesterol. While the findings are encouraging, the researchers stress this is an early-stage study with a small participant pool and short follow-up.
Safety remains a priority. The team is monitoring for unintended genetic edits and longer-term effects as more patients are enrolled in larger trials before any regulatory steps.
If confirmed in larger studies, the therapy could complement existing treatments and shift how doctors manage hard-to-treat lipid disorders, potentially lowering cardiovascular risk on a broader scale.
This milestone underscores the promise of gene editing in metabolic medicine, even as experts urge cautious optimism and rigorous long-term data.
Cover image source: Amgen cholesterol drug cuts risk of first cardiac event by 25% 🔗
